Skip to main content

Table 2 Changes in cognitive and global performance, and dose of cholinesterase inhibitors, during 3 years of therapy, by age-at-onset group

From: Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years

Number of patients with EOAD/LOAD

MMSE score/MMSE change from baselinea

ADAS-Cog score (0–70)/ADAS-Cog change from baselinea

CIBIC score, % of improved or unchanged remaining patients

ChEI dosea,b

EOAD

LOAD

p Value

EOAD

LOAD

p Value

EOAD

LOAD

p Value

EOAD

LOAD

p Value

2 months (n = 138/827)

22.5 (21.7, 23.3)/1.1 (0.7, 1.6)

22.3 (22.1, 22.6)/0.9 (0.7, 1.1)

0.674/0.313

NA

NA

NA

90

93

0.261

63 (60, 67)

61 (59, 62)

0.160

6 months (n = 126/752)

21.6 (20.7, 22.5)/0.4 (−0.2, 0.9)

21.8 (21.5, 22.1)/0.4 (0.2, 0.7)

0.671/0.829

20.7 (18.8, 22.6)/−1.2 (−2.5, 0.2)

20.4 (19.7, 21.1)/0.1 (−0.4, 0.6)

0.747/0.055

76

76

0.978

71 (67, 75)

68 (67, 70)

0.233

12 months (n = 111/669)

20.2 (19.0, 21.4)/−1.0 (−1.8, −0.2)

21.1 (20.7, 21.5)/−0.5 (−0.8, −0.2)

0.169/0.218

23.3 (20.7, 25.9)/−3.5 (−5.4, −1.7)

21.5 (20.7, 22.3)/−1.6 (−2.1, −1.0)

0.199/0.045

49

57

0.116

80 (76, 84)

73 (71, 75)

0.005

18 months (n = 101/530)

20.1 (18.9, 21.3)/−1.5 (−2.3, −0.7)

20.4 (19.9, 20.8)/−1.4 (−1.7, −1.0)

0.692/0.727

24.5 (21.7, 27.2)/−5.0 (−6.7, −3.4)

22.7 (21.7, 23.8)/−3.1 (−3.8, −2.4)

0.235/0.035

44

50

0.265

83 (79, 88)

77 (75, 79)

0.010

24 months (n = 84/480)

18.5 (16.9, 20.2)/−3.0 (−4.3, −1.7)

19.8 (19.3, 20.3)/−2.2 (−2.6, −1.8)

0.147/0.243

23.8 (20.3, 27.2)/−6.1 (−8.3, −3.9)

23.5 (22.3, 24.7)/−4.5 (−5.4, −3.7)

0.890/0.164

32

40

0.162

86 (82, 90)

78 (76, 80)

0.002

30 months (n = 66/346)

18.7 (16.7, 20.6)/−3.2 (−4.6, −1.7)

19.6 (19.0, 20.2)/−2.6 (−3.1, −2.1)

0.385/0.448

27.0 (22.7, 31.2)/−9.3 (−12.5, −6.1)

23.9 (22.5, 25.3)/−5.3 (−6.3, −4.2)

0.183/0.019

29

34

0.452

85 (80, 90)

78 (76, 81)

0.020

36 months (n = 57/318)

17.5 (15.4, 19.5)/−4.1 (−5.6, −2.6)

19.3 (18.6, 19.9)/−3.1 (−3.7, −2.6)

0.091/0.230

26.3 (21.4, 31.1)/−9.2 (−12.7, −5.7)

24.8 (23.2, 26.5)/−7.2 (−8.4, −6.0)

0.517/0.227

32

29

0.650

88 (83, 93)

80 (77, 82)

0.005

  1. ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, ChEI Cholinesterase inhibitor, CIBIC Clinician Interview-Based Impression of Change, EOAD Early-onset Alzheimer’s disease, LOAD Late-onset Alzheimer’s disease, MMSE Mini Mental State Examination, NA Not assessed
  2. For clarity, clinical improvements for both MMSE and ADAS-Cog scales have been tabulated as positive changes from the start of ChEI treatment (baseline)
  3. aMean (95% CI)
  4. bMean percentage of the maximum recommended dose, namely 10 mg for donepezil, 12 mg for rivastigmine and 24 mg for galantamine
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193